<?xml version="1.0" encoding="UTF-8"?>
<p>The patient was put on a combination of antiretrovirals including two nucleoside reverse transcriptase inhibitors (emtricitabine-tenofovir) and a non-nucleoside reverse transcriptase inhibitor (efavirenz). The development was marked by the complete disappearance of the pain and an important regression of the lesions after six months of treatment, with however the persistence of residual lymphoedema (
 <xref ref-type="fig" rid="fig2">Figure 2</xref>).
</p>
